Immatics N.V. (NASDAQ:IMTX) Receives $18.80 Average PT from Brokerages

Immatics N.V. (NASDAQ:IMTX) has received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $18.80.

Several equities analysts recently issued reports on IMTX shares. Guggenheim boosted their price target on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Zacks Research upgraded Immatics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 13th. Leerink Partners reissued an “outperform” rating and issued a $17.00 target price on shares of Immatics in a report on Thursday, December 4th. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Immatics in a report on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IMTX. SG Americas Securities LLC purchased a new position in Immatics during the fourth quarter worth about $2,189,000. Alyeska Investment Group L.P. acquired a new position in Immatics during the 3rd quarter worth approximately $2,556,000. Verition Fund Management LLC purchased a new position in shares of Immatics during the 3rd quarter worth approximately $385,000. Vestal Point Capital LP lifted its holdings in shares of Immatics by 1.6% in the 3rd quarter. Vestal Point Capital LP now owns 6,350,000 shares of the company’s stock valued at $54,102,000 after buying an additional 100,000 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Immatics by 4,991.1% in the 3rd quarter. Millennium Management LLC now owns 721,866 shares of the company’s stock valued at $6,150,000 after buying an additional 707,687 shares during the period. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Stock Up 4.8%

NASDAQ:IMTX opened at $9.83 on Thursday. The company has a market capitalization of $1.19 billion, a PE ratio of -9.64 and a beta of 1.36. Immatics has a 52-week low of $3.30 and a 52-week high of $12.41. The stock’s 50 day moving average price is $10.07 and its 200 day moving average price is $8.21.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings data on Monday, November 17th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. The company had revenue of $6.10 million during the quarter, compared to analysts’ expectations of $12.53 million. Immatics had a negative return on equity of 24.16% and a negative net margin of 146.13%. As a group, sell-side analysts anticipate that Immatics will post -0.72 EPS for the current fiscal year.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.